Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
|Articles|June 28, 2023
Sleep and Schizophrenia: Test Your Knowledge
Author(s)Brian Miller, MD, PhD, MPH
Test your knowledge on the latest research in sleep issues and schizophrenia.
Advertisement
Advertisement
Related to this article
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
2
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Neflamapimod for Dementia With Lewy Bodies Misses End Point, Subgroup Signal Emerges
5